Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
KPRX is the new symbol. Have traded not a lot but trying to average down in larger quantity about a thousand shares around $1.50, surely it will rally into the 2's for a scalp. The more I think about it, so lucky to get out in the 6s back in the summer, just proves you cant marry most stocks, take your profits. But I like $1.50-ish range.
Was starting to look at getting back in this. Look at all the selling though. According to finviz insiders only own 1% and the selling is marked as 96%
https://finviz.com/quote.ashx?t=EYEG
Guess I didn't mark my sell here. Sold 2.05 on the 14th. We'll see if this sets up closer to the $.
Looking good. 20dma crossing the 50dma. 200 dma is $4.19.
EYEG daily.
STRONG BUY $11 TARGET
https://www.nasdaq.com/market-activity/stocks/eyeg/analyst-research
I'm not the one making this up. Just a disclaimer. And I try and take the volatility of an entity into account after they do the sin of all stocks by doing a reverse split. The float is so small it can skyrocket and still close red in the same day. With something solid this may have a chance. Maybe their upcoming data will provide the catalyst.
GLTA $EYEG
Yes, I bought 1.85 and did do a quick swing here the other day premarket (Oct 1st) thought it would have more gusto. It may.
1.85 looks good to me. $$$ boogie time tomorrow maybe!
Back over $2 and on its way to 3. RIIIIP IT!!!
Rough day out there today for the markets. This can float on air easy enough with the small float it has.
going the wronge way
buying dip here
yup small float
More! Then acquisition.
well I couldnt help myself and bought some at 2.32 and 2.52, its extremely oversold, and due for a bounce to 3 or more.
Sold everything on the pre-market at 6.40 the other day, got out by the skin of the teeth, now look its at an all time low of 2.50. Maybe I would buy back in if cash allows, not right now.
WOW $EYEG YUUUUGE HITS!!
HUGE NEWS! MERGER!
Eyegate has been good to me ever time, took everything off the table in the pre-market around 7 bucks, thank goodness for the fidelity alerts though it went higher in the open anyway you never never know. Rebought a little at 5 but I will only buy further in the mid-4s and below.
* * $EYEG Video Chart 12-21-2020 * *
Link to Video - click here to watch the technical chart video
$EYEG is screaming for the top after announcing the acquisition of Panoptes Pharma, transforming its pipeline. https://cnafinance.com/eyeg-stock-eyegate-pharmaceuticals-acquires-panoptes-pharma/
Out EYEG $7.75 congrats all. I would have stuck around but I will be gone all day today.
$EYEG 7.41 CONGRAT$
DJ EyeGate Pharma Announces Transformative Acquisition Of Panoptes Pharma >EYEG
6:55 am ET December 21, 2020 (Dow Jones) Print
2020-12-21 11:55:00 GMT Press Release: EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma
EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma
Expands Pipeline Beyond Ophthalmology with PP-001, a Clinical Stage, Best-in-Class DHODH Inhibitor
PP-001 Leverages a Validated Immune Modulating Mechanism Optimized for Increased Specificity and Picomolar Potency to Avoid Off-Target Side Effects
Acquisition Strengthens Leadership Team with Appointment of Panoptes Co-Founders Dr. Franz Obermayr as EVP Clinical Development and Dr. Stefan Sperl as EVP CMC and Operations
WALTHAM, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or "the Company"), a clinical stage company focused on developing products for treating disorders of the eye, today announced the acquisition of Panoptes Pharma ("Panoptes"), a privately-held clinical stage biotech company focused on developing a novel proprietary small molecule for the treatment of severe eye diseases with a high unmet medical need.
The acquisition transforms EyeGate's pipeline with the addition of PP-001, a next-generation, non-steroidal, immuno-modulatory, small molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH) with potential best-in-class picomolar potency. PP-001 was rationally designed to overcome the off-target side effects and safety issues associated with DHODH inhibitors, a validated drug class with broad potential in inflammatory, viral and oncology indications. First-in-class in ophthalmology, PP-001 has been developed in two clinical-stage ophthalmic formulations; PaniJect, an intravitreal injection for inflammatory diseases of the eye including posterior uveitis with Phase 1b/2a safety and efficacy data and PaniDrop, an eye drop for viral conjunctivitis and dry eye disease with completed Phase 1 safety data. In addition, a clinical-stage intravenous (IV) formulation of PP-001 is being evaluated as an antiviral and the company intends to soon complete development of an oral formulation for neurological and autoimmune indications.
"The acquisition of Panoptes propels the EyeGate pipeline forward to include a de-risked clinical-stage candidate with broad potential across a diverse range of ocular, autoimmune and neurological indications," said Stephen From, Chief Executive Officer of EyeGate. "While DHODH inhibitors have been successfully developed for a range of autoimmune conditions, their utility has been limited due to tolerability and safety concerns. We believe PP-001, with potential best-in-class specificity and potency, has overcome these limitations to deliver this validated mechanism in inflammatory diseases of the eye as well as diseases beyond the ophthalmic space. With promising clinical safety and efficacy data in hand, and ophthalmic formulations to target indications with a medical need on the ocular surface and the back-of-the-eye, we are poised to begin a robust clinical program for PP-001."
Mr. From continued, "In addition to this transformative asset, we are also pleased to welcome Panoptes cofounders Dr. Franz Obermayr and Dr. Stefan Sperl to the EyeGate management team, whose proven track records and extensive experience executing on clinical development strategies will enable our rapid advancement into indications outside of ophthalmology. I am confident this strengthened team positions the new EyeGate to maximize the clinical potential of PP-001 as a best-in-class immunomodulator, while also complementing our existing pipeline of late-stage ocular assets which together have the potential to address significant unmet needs and large market opportunities."
Dr. Franz Obermayr, co-founder and Chief Executive Officer of Panoptes, and EVP Clinical Development of EyeGate, said, "This acquisition by EyeGate, a clinical-stage public company with an ophthalmology focus, is testament to the Panoptes team's success in developing our novel and highly innovative products. I look forward to joining the EyeGate team to unlock the clinical potential of PP-001 across a diverse set of indications with high unmet medical need."
Under the terms of the agreement, Panoptes will become a wholly owned subsidiary of EyeGate. The consideration from EyeGate (subject to certain adjustments) is $4,000,000 at close consisting of EyeGate common stock, EyeGate preferred stock and cash. Additionally, $1,500,000 in consideration is held back and will be issued in EyeGate preferred stock after a period of 18 months, subject to adjustments for post-closing working capital or indemnification obligations. The transaction also includes two cash or share earn-out provisions, each calling for an additional payment of up to $4,750,000 contingent upon 1) the enrollment and randomization of a first patient into the first Phase III pivotal study of any Panoptes ophthalmic product with the FDA, and 2) an approval of a New Drug Application ("NDA") by the FDA with respect to any Panoptes ophthalmic product.
About Panoptes
The privately held biotech company Panoptes Pharma GmbH was founded by Dr. Franz Obermayr and Dr. Stefan Sperl and is located in Vienna, Austria. The highly experienced team of Panoptes has successfully developed PP-001 a third generation nanomolar inhibitor of DHODH as an intravitreal, eye drop and intravenous formulation for a wide area of indications in ophthalmology and beyond. Panoptes has achieved major clinical milestones and has shown for the first time that PP-001 is efficacious and safe as an intravitreal injection (PaniJect) in non-infectious posterior segment uveitis patients. Panoptes also developed a novel nano carrier technology for eye drops to revolutionize the treatment of ocular surface diseases and has shown in a clinical safety study that this novel eyedrop, PaniDrop, is well tolerated and safe.
About EyeGate
EyeGate is a clinical-stage specialty pharmaceutical company focused on developing and commercializing products for treating diseases and disorders of the eye. EyeGate's lead product, Ocular Bandage Gel ("OBG"), is based on a modified form of the natural polymer hyaluronic acid. The objective of OBG is to protect the ocular surface in order for the body to re-epithelialize the cornea and improve ocular surface integrity. The product is applied as a clear topical gel, to the damaged ocular surface, and possesses unique properties that help hydrate and protect the ocular surface to allow for wound healing. EyeGate is in clinical evaluation for two different patient populations: (1) patients undergoing photorefractive keratectomy ("PRK") surgery to demonstrate corneal wound repair after refractive surgery; and (2) patients with punctate epitheliopathies ("PE") as a result of dry eye to promote reduction of PEs. For more information, please visit www.EyeGatePharma.com.
* * $EYEG Video Chart 08-12-2020 * *
Link to Video - click here to watch the technical chart video
News: $EYEG EyeGate Pharma Confirms Path Forward with FDA To Develop Combination Product
WALTHAM, MA / ACCESSWIRE / August 12, 2020 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has received positive feedback following its pre-IND meeti...
Find out more EYEG - EyeGate Pharma Confirms Path Forward with FDA To Develop Combination Product
* * $EYEG Video Chart 03-31-2020 * *
Link to Video - click here to watch the technical chart video
Looks like a big mover today
Smart money flies, dumb money cries. I agree eyeg is doing great, especially via fundamentals.
$EYEG: People forgetting about this ? toooooo bad
This is the play for 2020.
Warrants at only $0.02........... stupid low
Stupid stupid low.
Ready to ROLL BIGggggggg time.
GO $EYEG
I got stabbed with this falling knife...I’ll wait a bit before I pull it out.
I hope so.
It would be pretty lonely otherwise. :)
Just sitting on my shares waiting for news.
After Hours bid of $12.60 now with 3600 on the bid. Wow!
Total volume 646,000 shares. Somebody sure is confident of good news...
SOON!
Ever since EYEG announced they will consider "strategic alternatives"
before they need more cash for operations, the stock has moved up
aggressively on heavy volume despite the ultra-low float. Perhaps
a buyer will step up now, instead of waiting for dilution. BHC has a
10 billion market cap...they could buy this for next to nothing and
end up with additional $100's of millions in future annual revenues.
I'd expect a takeout in the mid twenties...roughly $100 million or
1% of BHC's market cap. Just an eventual $30 million in revenues
would justify a $100 million buyout. Quite obviously, if EYEG is
acquired by a major player they can set whatever price the market
will pay for the product. This is just my own speculation...so be
careful, but I think the mid-twenties is in the cards here.
If this makes sense to those here you might want to look at AMRN
which may also be a solid takeout candidate. Maybe a BP wants to
be involved in taking this through the FDA process. (EYEG that is.)
* * $EYEG Video Chart 11-22-2019 * *
Link to Video - click here to watch the technical chart video
then to 8.75 some stocks take days to move .20 this moves .50 in minutes
have to trade this
cant hold this
lol
I am watching! EYEG...
9.15 again
its trying
Could see huge 11.00+ pop & drop @ opening bell!
swings hard just went from 8.80 to 9.75 back to 8.54 all within 5mins
very volatile swings
here is a dip buy for a flip
Filled Buy 500 EYEG Limit 8.60 -- -- 08:46:40 11/22/19
More topline data coming in 2K20.
9.01 after hitting 11
EYEG
Message in reply to:
They also had shelf placement 3 days ago.
Followers
|
26
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
418
|
Created
|
07/20/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |